<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03898882</url>
  </required_header>
  <id_info>
    <org_study_id>201810134</org_study_id>
    <nct_id>NCT03898882</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Oxytocin at Cesarean Delivery</brief_title>
  <acronym>Peacocks</acronym>
  <official_title>The Pharmacokinetics of Oxytocin in Pregnant Women Undergoing Cesarean Delivery - a Feasibility Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to obtain data to inform the design of a population pharmacokinetic
      study of oxytocin after administration at CD as per standard institutional practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this pilot study the investigators will compare plasma oxytocin concentrations measured in
      arterial and venous blood, after oxytocin administration at cesarean delivery, in order to
      assess the validity of venous samples. They will also measure oxytocinase to explore how
      levels vary around the time of delivery of the placenta and to assess the effect that this
      may have on the metabolism of oxytocin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2019</start_date>
  <completion_date type="Actual">February 28, 2020</completion_date>
  <primary_completion_date type="Actual">February 28, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial [OXT]</measure>
    <time_frame>Scheduled samples during the first 30 minutes after oxytocin administration</time_frame>
    <description>Concentration of oxytocin in arterial samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Venous [OXT]</measure>
    <time_frame>Scheduled samples during the first 30 minutes after oxytocin administration</time_frame>
    <description>Concentration of oxytocin in venous samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial [OXTase]</measure>
    <time_frame>Scheduled samples during the first 30 minutes after oxytocin administration</time_frame>
    <description>Concentration of oxytocinase in arterial samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine tone</measure>
    <time_frame>Scheduled measurements during the first 30 minutes after oxytocin administration</time_frame>
    <description>Uterine tone measured using a Shore Durometer or assessed by obstetrician using numerical rating score (NRS, 0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypotension</measure>
    <time_frame>Measured intraoperatively</time_frame>
    <description>Incidence of systolic BP reduced by 20% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea &amp; Vomiting</measure>
    <time_frame>Recorded intraoperatively</time_frame>
    <description>Incidence of nausea and vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EBL</measure>
    <time_frame>Estimated at the end of surgery</time_frame>
    <description>Estimated blood loss in milliliters</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>BMI 20 - 29.9 kg/m2</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>BMI &gt; 30 kg/m2</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin</intervention_name>
    <description>PK measurements of oxytocin</description>
    <arm_group_label>BMI 20 - 29.9 kg/m2</arm_group_label>
    <arm_group_label>BMI &gt; 30 kg/m2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Shore durometer</intervention_name>
    <description>The investigators will take serial readings from a digital durometer at the uterine fundus at 3, 6, 9 and 12 minutes following OXT administration to provide data that will inform an estimate of the timing of peak effect. Shore durometers measure the hardness of materials on a scale of 0-100 Shore Units (SU). Preliminary (unpublished) data provided a range of 10-56 SU after oxytocin administration at cesarean delivery. Durometer readings were also shown to correlate positively with the obstetrician's manual assessment of uterine contractility, which is traditionally used to determine the success or failure of uterotonic therapy.</description>
    <arm_group_label>BMI 20 - 29.9 kg/m2</arm_group_label>
    <arm_group_label>BMI &gt; 30 kg/m2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women scheduled for cesarean delivery of their babies at term
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Term singleton pregnancy

          -  Age 18-45 years of age

          -  ASA classification 2 or 3

          -  Scheduled cesarean delivery under neuraxial anaesthesia

        Exclusion Criteria:

          -  Age or ASA classification outside of inclusion criteria

          -  Need for general anaesthesia

          -  Absence of consent

          -  Inability to communicate in English or other barrier to providing informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Participants must be scheduled for cesarean delivery of their baby</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David T Monks, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, Gülmezoglu AM, Temmerman M, Alkema L. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014 Jun;2(6):e323-33. doi: 10.1016/S2214-109X(14)70227-X. Epub 2014 May 5. Review.</citation>
    <PMID>25103301</PMID>
  </reference>
  <reference>
    <citation>Attilakos G, Psaroudakis D, Ash J, Buchanan R, Winter C, Donald F, Hunt LP, Draycott T. Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double-blind randomised trial. BJOG. 2010 Jul;117(8):929-36. doi: 10.1111/j.1471-0528.2010.02585.x. Epub 2010 May 19.</citation>
    <PMID>20482535</PMID>
  </reference>
  <reference>
    <citation>Chiou WL. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II). Clin Pharmacokinet. 1989 Oct;17(4):275-90. Review.</citation>
    <PMID>2686884</PMID>
  </reference>
  <reference>
    <citation>Chiou WL. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part I). Clin Pharmacokinet. 1989 Sep;17(3):175-99. Review.</citation>
    <PMID>2680213</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 29, 2019</study_first_submitted>
  <study_first_submitted_qc>March 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

